Bpifrance

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing novel treatments for advanced liver diseases. Founded in 2019, the company aims to address conditions such as liver fibrosis, cirrhosis, and liver cancer, particularly targeting Claudin-1 positive tumors and organ fibrosis. Alentis employs a research platform that utilizes clinically relevant readouts and single-cell RNA sequencing of patient liver tissues, enabling the development of effective therapies to combat fibrosis and reverse the progression of these diseases. Through its innovative approach, Alentis Therapeutics seeks to improve outcomes for patients suffering from severe liver-related health issues.

Edaphos is an international holding company providing eco-friendly soil remediation solutions to transform waste and barren soil into fertile soil.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing novel treatments for advanced liver diseases. Founded in 2019, the company aims to address conditions such as liver fibrosis, cirrhosis, and liver cancer, particularly targeting Claudin-1 positive tumors and organ fibrosis. Alentis employs a research platform that utilizes clinically relevant readouts and single-cell RNA sequencing of patient liver tissues, enabling the development of effective therapies to combat fibrosis and reverse the progression of these diseases. Through its innovative approach, Alentis Therapeutics seeks to improve outcomes for patients suffering from severe liver-related health issues.

VectivBio is a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases. They are committed to pursuing rare diseases with well-defined biology that can be targeted with best-in-disease therapies that have the potential to meaningfully transform and improve the lives of patients and their families, not just provide an incremental improvement or benefit over the standard-of-care. It was founded as a spinout from Therachon, a biotechnology company acquired by Pfizer for its program in achondroplasia. VectivBio was incorporated in 2019 and is based in Basel, Switzerland.

Multiwave Imaging is a French company recognized as a leader in the design of metamaterial MRI antennas. It operates as a wholly owned subsidiary of Multiwave Technologies AG, which was founded in Switzerland in March 2015 and has its headquarters in Geneva. The company focuses on developing innovative metamaterial technologies aimed at enhancing quality of life. Multiwave Imaging's primary objective is to create and harness intellectual property, assess its commercial viability, and establish management teams to transform these innovations into marketable products. This strategic approach enables Multiwave Imaging to build companies across various sectors, leveraging advanced technology to address diverse needs.

Multiwave Imaging is a French company recognized as a leader in the design of metamaterial MRI antennas. It operates as a wholly owned subsidiary of Multiwave Technologies AG, which was founded in Switzerland in March 2015 and has its headquarters in Geneva. The company focuses on developing innovative metamaterial technologies aimed at enhancing quality of life. Multiwave Imaging's primary objective is to create and harness intellectual property, assess its commercial viability, and establish management teams to transform these innovations into marketable products. This strategic approach enables Multiwave Imaging to build companies across various sectors, leveraging advanced technology to address diverse needs.

VectivBio is a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases. They are committed to pursuing rare diseases with well-defined biology that can be targeted with best-in-disease therapies that have the potential to meaningfully transform and improve the lives of patients and their families, not just provide an incremental improvement or benefit over the standard-of-care. It was founded as a spinout from Therachon, a biotechnology company acquired by Pfizer for its program in achondroplasia. VectivBio was incorporated in 2019 and is based in Basel, Switzerland.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing novel treatments for advanced liver diseases. Founded in 2019, the company aims to address conditions such as liver fibrosis, cirrhosis, and liver cancer, particularly targeting Claudin-1 positive tumors and organ fibrosis. Alentis employs a research platform that utilizes clinically relevant readouts and single-cell RNA sequencing of patient liver tissues, enabling the development of effective therapies to combat fibrosis and reverse the progression of these diseases. Through its innovative approach, Alentis Therapeutics seeks to improve outcomes for patients suffering from severe liver-related health issues.

Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. Therachon is headquartered in Basel, Switzerland, with research labs in Nice, France.

NeoXam provides asset management and capital market firms with cost-efficient, proven, and mission-critical solutions. NeoXam is a financial software company, delivering solutions and services for 150+ customers in 25 countries worldwide. NeoXam is committed to its clients’ success, delivering reliable and scalable solutions, processing more than $14 trillion worth of assets per day and serving over 10,000 users. Through its combined talents and transparent approach, NeoXam helps buy- and sell-side players address the continuous changes in the financial market industry, to grow and better serve their clients. NeoXam relies on 450+ staff with offices in Paris, Frankfurt, Luxembourg, Zurich, Geneva, Milan, New York, Boston, Hong Kong, Shanghai, Beijing, Tunis and Cape Town.

Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. Therachon is headquartered in Basel, Switzerland, with research labs in Nice, France.

Webmecanik is a marketing automation vendor powered by Mautic. Their proprietary agency dashboard (myWebmecanik) makes deploying new instances and managing client accounts a breeze for marketing agencies. With humble beginnings in Annecy, France; Webmecanik now has offices and employees spread accross Paris, Berlin, and Geneva. Staying true to their European roots, all client data and automation instances are hosted exclusively in Europe; with clients having the choice between France, Switzerland, and Germany.

Recommerce Group specializes in the trade-in and remarketing of second-hand mobile phones, offering a comprehensive range of solutions for the refurbishment and resale of smartphones. The company employs advanced proprietary technologies to give new life to used devices, facilitating both buyback and resale processes. Its services encompass multi-channel trade-in solutions, including reverse logistics, data erasure, and customer support, as well as graphic design and web development for marketing initiatives. Recommerce Group also provides rental options for smartphones and tablets on flexible terms. Operating internationally, the company collaborates with prominent retailers and mobile network operators in France, Switzerland, and Spain, while maintaining a network of physical and online distribution channels. Founded in 2009 and headquartered in Paris, France, Recommerce Group also has additional offices in Grenoble, Warsaw, Madrid, and Fribourg, positioning itself as a leader in the European recommerce market.